Overview
- FDA Commissioner Marty Makary confirmed there are no current plans to impose new restrictions on mifepristone access, despite ongoing pressure from anti-abortion groups.
- Makary emphasized that any future regulatory changes would depend on new safety data, reiterating the agency's reliance on evidence-based decision-making.
- Mifepristone, approved in 2000 and paired with misoprostol, is used in the majority of U.S. medication abortions and has been extensively studied for safety and efficacy.
- The Supreme Court previously dismissed a legal challenge by anti-abortion groups seeking to restrict mifepristone, citing lack of standing.
- Makary's comments mark a firmer stance compared to his Senate confirmation hearing, where he pledged to review data but did not commit to specific actions.